Kilder

Artritter: 

Van Venrooij WJ, van Beers JBC, Pruij GJM. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann NY Acad Sci 2008;1143:268-285 

Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 2004;50:709-15 

Horton, DB, Scott FI, Heynes K, Putt ME, Rose CD, Lewis JD, Strom BL: Antibiotic exposure and juvenile idiopathic arthritis: A case-control study. Pediatrics Vol 136, num. 2, Aug 2015 

Kiely PDW, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009;48:765-72 

Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637 

Flatø B, Vinje O. Epidemiologien ved juvenil idiopatisk artritt og andre artritter i barnealderen. Norsk epidemiologi 2008;18:93-8 

Eilertsen GØ, Becker-Merok A, Nossent JC. The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management. J Rheumatol 2009;36:552-9 

Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Reports of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008;67:195-205 

Brun JG, Jonsson R. Sjögrens syndrom. Norsk epidemiologi 2008; 18 (1): 67-72 

Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American European Consensus Group. Ann Rheum Dis 2002;61:554-8 

Kowal-Bielecka O, Landewe R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 2009;68:620-8 

Chakravarty K, Elgabani SH, Scott DG, Merry P. A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994;33:152-6 

Salvarini C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45 

Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23 

Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24 

Pascual E, Sivera F. Therapeutic advanced in gout. Curr Opin Rheumatol 2007;19:122-7 

Thabet MM et al, Arthritis Res Ther 2009; 11:R155 og De Rooy DPC et al, Rheumatology 2011: 50, 93-100. 

Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis 2005;64:594-598

Townes JM. Reactive Arthritis after Enteric Infections in the United States: The Problem of Definition. Clinical Infectious Diseases 2010;50:247-54 

Watts RA, Scott DGI. Recent developements in the classification and assessment of vasculitis. Best Practice&Research Clinical Rheumatology 2009;23:429-43 

Pagnoux C et al. Clinical Features and Outcomes in 348 Patients with Polyartheritis Nodosa. Arthritis Rheum 2010;62:616-26 

Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2017 Jun 16. pii: S0883-5403(17)30401-1. doi: 10.1016/j.arth.2017.05.001. (Systematic Review) PMID: 28629905